Table 1.
Characteristics of participants in this substudy.
| Placebo arm n=39 | Bamlanivimab arm n=30 | |
|---|---|---|
| Age - median (range) | 50 (20–71) | 50.5 (25–73) |
| Race – White n (%) | 33 (85%) | 29 (97%) |
| Ethnicity – Hispanic or Latino n (%) | 10 (26%) | 3 (10%) |
| Gender – Female n (%) | 24 (62%) | 15 (50%) |
| Comorbidities – At least one n (%) | 12 (31%) | 15 (50%) |
| Days of symptoms before enrollment – median (range) | 4 (1–10) | 5 (3–8) |
| Seropositive at baseline (%)1 | 0 (0%) | 1 (3%) |
1
4 placebo and 2 intervention arm participants had unknown serostatus at baseline